Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Bordignon

Showing results (91-100 of 100) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 100 results.
British Journal of Cancer|July 2, 2009
Phase Ib study of NGR-hTNF, a selective vascular targeting agent, administered at low doses in combination with doxorubicin to patients with advanced solid tumoursV Gregorc, A Santoro, E Bennicelli, et al.
British Journal of Cancer|May 31, 2012
Phase II study of NGR-hTNF in combination with doxorubicin in relapsed ovarian cancer patientsD Lorusso, G Scambia, G Amadio, et al.
Bone Marrow Transplantation|June 4, 2015
Haploidentical HSCT: a 15-year experience at San RaffaeleC Bonini, J Peccatori, M T L Stanghellini, et al.
British Journal of Cancer|August 19, 2010
Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinomaA Santoro, T Pressiani, G Citterio, et al.
British Journal of Cancer|November 22, 2012
Phase I and pharmacodynamic study of high-dose NGR-hTNF in patients with refractory solid tumoursP A Zucali, M Simonelli, F De Vincenzo, et al.
Leukemia|May 2, 2008
Genomic typing for patient-specific human leukocyte antigen-alleles is an efficient tool for relapse detection of high-risk hematopoietic malignancies after stem cell transplantation from alternative donorsB Mazzi, T D Clerici, M Zanussi, et al.
Bone Marrow Transplantation|June 16, 2015
Early recovery of CMV immunity after HLA-haploidentical hematopoietic stem cell transplantation as a surrogate biomarker for a reduced risk of severe infections overallM Noviello, A Forcina, V Veronica, et al.
Leukemia|November 6, 2014
Incidence, risk factors and clinical outcome of leukemia relapses with loss of the mismatched HLA after partially incompatible hematopoietic stem cell transplantationL Crucitti, R Crocchiolo, C Toffalori, et al.
Leukemia|June 5, 2014
Sirolimus-based graft-versus-host disease prophylaxis promotes the in vivo expansion of regulatory T cells and permits peripheral blood stem cell transplantation from haploidentical donorsJ Peccatori, A Forcina, D Clerici, et al.
Nature Medicine|April 2, 2003
Safety of retroviral gene marking with a truncated NGF receptorC Bonini, M Grez, C Traversari, et al.
Pageof 10

Showing results (91-100 of 100) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 100 results.
British Journal of Cancer|July 2, 2009
Phase Ib study of NGR-hTNF, a selective vascular targeting agent, administered at low doses in combination with doxorubicin to patients with advanced solid tumoursV Gregorc, A Santoro, E Bennicelli, et al.
British Journal of Cancer|May 31, 2012
Phase II study of NGR-hTNF in combination with doxorubicin in relapsed ovarian cancer patientsD Lorusso, G Scambia, G Amadio, et al.
Bone Marrow Transplantation|June 4, 2015
Haploidentical HSCT: a 15-year experience at San RaffaeleC Bonini, J Peccatori, M T L Stanghellini, et al.
British Journal of Cancer|August 19, 2010
Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinomaA Santoro, T Pressiani, G Citterio, et al.
British Journal of Cancer|November 22, 2012
Phase I and pharmacodynamic study of high-dose NGR-hTNF in patients with refractory solid tumoursP A Zucali, M Simonelli, F De Vincenzo, et al.
Leukemia|May 2, 2008
Genomic typing for patient-specific human leukocyte antigen-alleles is an efficient tool for relapse detection of high-risk hematopoietic malignancies after stem cell transplantation from alternative donorsB Mazzi, T D Clerici, M Zanussi, et al.
Bone Marrow Transplantation|June 16, 2015
Early recovery of CMV immunity after HLA-haploidentical hematopoietic stem cell transplantation as a surrogate biomarker for a reduced risk of severe infections overallM Noviello, A Forcina, V Veronica, et al.
Leukemia|November 6, 2014
Incidence, risk factors and clinical outcome of leukemia relapses with loss of the mismatched HLA after partially incompatible hematopoietic stem cell transplantationL Crucitti, R Crocchiolo, C Toffalori, et al.
Leukemia|June 5, 2014
Sirolimus-based graft-versus-host disease prophylaxis promotes the in vivo expansion of regulatory T cells and permits peripheral blood stem cell transplantation from haploidentical donorsJ Peccatori, A Forcina, D Clerici, et al.
Nature Medicine|April 2, 2003
Safety of retroviral gene marking with a truncated NGF receptorC Bonini, M Grez, C Traversari, et al.
Pageof 10